SynthesisScientific reports2016
Diagnostic test accuracy of anti-glycopeptidolipid-core IgA antibodies for Mycobacterium avium complex pulmonary disease: systematic review and meta-analysis.
Synthesis in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- Interferon-γ-response to mycobacterial glycopeptidolipids in patients with pulmonary non-tuberculous mycobacterial infection.Medical microbiology and immunology · 2026Article
- Nontuberculous mycobacterium seroprevalence in Japanese patients with RA.Rheumatology advances in practice · 2026Article
- Detection, Isolation, and Identification of Mycobacteria That Cause Nontuberculous Mycobacterial Disease and Tuberculosis.Pathogens (Basel, Switzerland) · 2025Review
- Environmental intervention for two cases of non-tuberculous mycobacterial disease.Nagoya journal of medical science · 2025Article
- Article
- Serodiagnosis ofIJTLD open · 2024Article
- Epidemiology of bronchiectasis at a single center in Japan: a retrospective cohort study.BMC pulmonary medicine · 2024Observational
- Is It Time to Say Goodbye to Sputum?American journal of respiratory and critical care medicine · 2024Article
- Time to diagnosis of nontuberculous mycobacterial pulmonary disease and longitudinal changes on CT before diagnosis.Heliyon · 2024Article
- Article
- Efficacy of three sputum specimens for the diagnosis of Mycobacterium avium complex pulmonary disease.BMC pulmonary medicine · 2023Review
- Detection ofInfection and drug resistance · 2023Article
- Antigen-specific cytokine profiles for pulmonaryFrontiers in immunology · 2023Article
- Use of Anti-Glycopeptidolipid-Core Antibodies Serology for Diagnosis and Monitoring ofOpen forum infectious diseases · 2022Article
- Beyond antibiotics: recent developments in the diagnosis and management of nontuberculous mycobacterial infection.Breathe (Sheffield, England) · 2022Review
- The Diagnosis of Nontuberculous Mycobacterial Pulmonary Disease by Single Bacterial Isolation Plus Anti-GPL-Core IgA Antibody.Microbiology spectrum · 2022Article
- Correlation between serum carbohydrate antigen 19-9 levels and computed tomography severity score in patients with nontuberculous mycobacterial pulmonary disease.Scientific reports · 2021Article
- Serological diagnosis ofJournal of clinical tuberculosis and other mycobacterial diseases · 2020Article
- Host Immune Response and Novel Diagnostic Approach to NTM Infections.International journal of molecular sciences · 2020Review
- The impact of adjuvant surgical treatment of nontuberculous mycobacterial pulmonary disease on prognosis and outcome.Respiratory research · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Currently, an anti-glycopeptidolipid (GPL)-core IgA antibody assay kit for diagnosing Mycobacterium avium complex (MAC) is commercially available. We conducted this systematic review and meta-analysis to reveal the precise diagnostic accuracy of anti-GPL-core IgA antibodies for MAC pulmonary disease (MAC-PD). We systematically searched reports that could provide data for both sensitivity and specificity by anti-GPL-core IgA antibody for clinically diagnosed MAC-PD. Diagnostic test accuracy was estimated using the bivariate model. Of the 257 articles that we had found through primary search, we finally included 16 reports consisted of 1098 reference positive subjects and 2270 reference negative subjects. The diagnostic odds ratio was 24.8 (95% CI 11.6-52.8, I(2) = 5.5%) and the area under the hierarchical summary receiver operating characteristic curves was 0.873 (95% CI 0.837-0.913). With a cutoff value of 0.7 U/mL, the summary estimates of sensitivity and specificity were 0.696 (95% CI 0.621-0.761) and 0.906 (95% CI 0.836-0.951), respectively. The positive and negative likelihood ratios were 7.4 (95% CI 4.1-13.8) and 0.34 (95% CI 0.26-0.43), respectively. The demanding clinical diagnostic criteria may be a cause of false positive of the index test. The index test had good overall diagnostic accuracy and was useful to ruling in MAC-PD with the cutoff value.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.